Osteoporosis management in a Medicaid population after the Women's Health Initiative study

Journal of Women's Health

Volumn 15, Issue 2, 2006, Pages 155-161

  Lee, Euni ^a   Wutoh, Anthony K ^a   Xue, Zhenyi ^a   Hillman, Jennifer J ^b   Zuckerman, Ilene H ^c  

^a HOWARD UNIVERSITY   (United States)

^b McAllen Medical Center   (United States)

^c UNIVERSITY OF MARYLAND   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; CALCITONIN; ESTROGEN; ETIDRONIC ACID; INSULIN; ORAL ANTIDIABETIC AGENT; PAMIDRONIC ACID; RALOXIFENE; RISEDRONIC ACID; SELECTIVE ESTROGEN RECEPTOR MODULATOR; TILUDRONIC ACID; ZOLEDRONIC ACID;

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; DRUG SURVEILLANCE PROGRAM; FEMALE; HORMONE SUBSTITUTION; HUMAN; MAJOR CLINICAL STUDY; MEDICAID; OSTEOPOROSIS; POSTMENOPAUSE; PREVALENCE; PRIORITY JOURNAL; RACE DIFFERENCE; SOCIAL STATUS; TIME SERIES ANALYSIS; UNITED STATES; WOMEN'S HEALTH;

AGED; AGED, 80 AND OVER; ALENDRONATE; BONE DENSITY CONSERVATION AGENTS; CALCITONIN; COHORT STUDIES; DIPHOSPHONATES; DRUG UTILIZATION; ESTROGEN RECEPTOR MODULATORS; ESTROGENS; ETIDRONIC ACID; FEMALE; HUMANS; MEDICAID; MIDDLE AGED; OSTEOPOROSIS, POSTMENOPAUSAL; OUTCOME ASSESSMENT (HEALTH CARE); PENNSYLVANIA; PHYSICIAN'S PRACTICE PATTERNS; WOMEN'S HEALTH SERVICES;

EID: 33645647804     PISSN: 15409996     EISSN: None     Source Type: Journal    
DOI: 10.1089/jwh.2006.15.155     Document Type: Article

References (20)

1. Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women. JAMA 2002;288:321.
2. U.S. Food and Drug Administration. FDA approves new labels for estrogen and estrogen with progestin therapies for postmenopausal women following review of Women's Health Initiative Data. FDA News. Available at www.fda.gov/bbs/topics/NEWS/2003/NEW00863.html Accessed February 14, 2005.
3. American Association of Clinical Endocrinology Osteoporosis Task Force. American Association of Clinical Endocrinologists medical guidelines for clinical practice for the prevention and treatment of postmenopausal osteoporosis: 2001 edition. With selected updates for 2003. Endocr Pract 2003;9:544.
4. U.S. Food and Drug Administration. Consumer information sheet: ibandronate sodium (marketed as Boniva). Available at www.fda.gov/cder/consumerinfo/druginfo/boniva.HTM Accessed October 17, 2005.
5. U.S. Food and Drug Administration. FDA updates hormone therapy information for postmenopausal women. FDA News. Available at www.fda.gov/bbs/topics/NEWS/2004/NEW01022.html Accessed February 20, 2005.
6. Hillman JJ, Zuckerman IH, Lee E. The impact of the Women's Health Initiative on hormone replacement therapy in a Medicaid program. J Womens Health 2004;13:986.
7. Majumdar SR, Almasi EA, Stafford RS. Promotion and prescribing of hormone therapy after report of harm by the Women's Health Initiative. JAMA 2004;292:1983.
8. McIntosh J, Blalock SJ. Effects of media coverage of Women's Health Initiative study on attitudes and behavior of women receiving hormone replacement therapy. Am J Health-Syst Pharm 2005;62:69.
9. Bestul MB, McCollum M, Hansen LB, Saseen JJ. Impact of the women's health initiative trial results on hormone replacement therapy. Pharmacotherapy 2004; 24:495.
10. Hersh AL, Stefanick ML, Stafford RS. National use of postmenopausal hormone therapy annual trends and responses to recent evidence. JAMA 2004;291:47.
11. Hass JS, Kaplan CP, Gerstenberger EP, Kerlikowske K. Changes in the use of postmenopausal hormone therapy after the publication of clinical trial results. Ann Intern Med 2004;140:184.
12. Lee E, Zuckerman IH, Weiss SR. Patterns of pharmacotherapy and counseling for osteoporosis management in visits to U.S. ambulatory care physicians by women. Arch Intern Med 2002;162:2362.
13. Alam NM, Archer JA, Lee E. Osteoporotic fragility fractures in African Americans: Under-recognized and undertreated. J Natl Med Assoc 2004;96:1640.
14. Chesnut CH III. Osteoporosis, an underdiagnosed disease. JAMA 2001;286:2865.
15. Cuddihy M, Amadio P, Meltoon LJ III. Patient barriers to osteoporosis interventions after fracture. Mayo Clin Proc 2002;77:875.
16. Nguyen TV, Center JR, Eisman JA. Osteoporosis: Underrated, underdiagnosed and undertreated. Med J Aust 2004;180 (Suppl 5):S18.
17. Vestergaard P, Rejnmark L, Mosekilde L. Osteoporosis is markedly underdiagnosed: A nationwide study from Denmark. Osteoporos Int 2005;16:134.
18. National Osteoporosis Foundation. America's bone health: The state of osteoporosis and low bone mass. Available at www.nof.org/advocacy/prevalence/ Accessed March 2, 2005.
19. Stafford RS, Drieling RL, Hersh AL. National trends in osteoporosis visits and osteoporosis treatment, 1988-2003. Arch Intern Med 2004;164:1525.
20. Lau HS, de Boer A, Beuning K, Porsius A. Validation of pharmacy records in drug exposure assessment. J Clin Epidemiol 1997;50:619.